Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos.
The major pathological lesion of Parkinson's disease (PD) is the selective cell death of dopaminergic (DA) neurons in substantia nigra (SN). Although the initial cause and subsequent molecular signaling mechanisms leading to DA cell death underlying the PD process remain elusive, brain-derived neurotrophic factor (BDNF) is thought to exert neuroprotective as well as neurotrophic roles for the survival and differentiation of DA neurons in SN. Addressing molecular mechanisms of BDNF action in both primary embryonic mesencephalic cultures and in vivo animal models has been technically difficult because DA neurons in SN are relatively rare and present with many heterogeneous cell populations in midbrain. We have developed and characterized a DA neuronal cell line of embryonic SN origin that is more accessible to molecular analysis and can be used as an in vitro model system for studying SN DA neurons. A clonal SN DA neuronal progenitor cell line SN4741, arrested at an early DA developmental stage, was established from transgenic mouse embryos containing the targeted expression of the thermolabile SV40Tag in SN DA neurons. The phenotypic and morphological differentiation of the SN4741 cells could be manipulated by environmental cues in vitro. Exogenous BDNF treatment produced significant neuroprotection against 1-methyl-4-phenylpyridinium, glutamate, and nitric oxide-induced neurotoxicity in the SN4741 cells. Simultaneous phosphorylation of receptor tyrosine kinase B accompanied the neuroprotection. This SN DA neuronal cell line provides a unique model system to circumvent the limitations associated with primary mesencephalic cultures for the elucidation of molecular mechanisms of BDNF action on DA neurons of the SN.
Son
J H
JH
Department of Neurology and Neuroscience, Cornell University Medical College and Laboratory of Molecular Neurobiology, The W. M. Burke Medical Research Institute, White Plains, New York 10605, USA.
Chun
H S
HS
Joh
T H
TH
Cho
S
S
Conti
B
B
Lee
J W
JW
D015655:1-Methyl-4-phenylpyridinium / Q000494:pharmacology; D000818:Animals; D019898:Autocrine Communication; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D004298:Dopamine / Q000502:physiology*; D015259:Dopamine Agents / Q000494:pharmacology; D004622:Embryo, Mammalian / Q000187:drug effects / Q000294:innervation; D051379:Mice; D008822:Mice, Transgenic; D009474:Neurons / Q000166:cytology / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010641:Phenotype; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects* / Q000196:embryology
D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine